Source: CureToday articles
Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, outperforming historical data.
Recent Content
- Medication Meltdown: Unpacking Drug Shortages
- Real-World Study Shows Comparable Survival Outcomes With First-Line Ibrutinib in High-Risk and Non-High-Risk CLL/SLL
- Gap-Scheduled Olaparib Plus Neoadjuvant Chemotherapy Improved Survival in Patients With gBRCAm TBNC
- Interferon Lowers Myelofibrosis Risk in Young Patients With Polycythemia Vera, Essential Thrombocytopenia
- Camber Pharmaceuticals Announces Addition of Temozolomide Capsules, USP
- Bladder Cancer Awareness Month Highlights the Importance of Early Detection
- Robotic Kidney Cancer Surgery May Aid Recovery, Spare Kidney Function
- FDA Approves Zynyz Treatment Regimen for Advanced Anal Cancer
- Evidence Over Anecdotes: The Misuse of Vitamin A During Measles Outbreaks
- The Promise of Psilocybin-Assisted Therapy for Opioid Use Disorder